weight loss drugs non glp 1 Unlocking The Power of GLP-1 For Life after weight-loss drugs

Although exploratory or post-hoc analyses of randomized trials [21, 22] suggest GLP1 receptor agonists versus placebo may protect against cognitive decline, complementary real-world evidence studies with rigorous methodology and sufficient events have been limited to three studies, [16, 23, 24] and the results are mixed

Results in real life can vary depending on individual factors, adherence and the kind of support people have in place

2016;11(3):e0150967

Add-on value of tirzepatide versus semaglutide

No formal matching was applied

The difference between the groups as measured by a test looking at someones tremors and rigidity was small, almost but not quite reaching what is deemed to be a clinically significant difference